John M. Kane, MD – Consultant and Speakers’ Bureau – Bristol-Myers Squibb, Janssen; Consultant – Abbott, Lilly, Pfizer, and Wyeth
John Kane M.D.
John M. Kane, MD
Chairman, Dept. of Psychiatry
The Zucker Hillside Hospital
Professor of Psychiatry, Neurology, and Neuroscience
The Albert Einstein College of Medicine
"John M. Kane, MD is Vice President for Behavioral Health Services of the North Shore - Long Island Jewish Health System and Chairman of Psychiatry at The Zucker Hillside Hospital. He is Professor of Psychiatry, Neurology and Neuroscience and holds the Dr. E. Richard Feinberg Chair in Schizophrenia Research at the Albert Einstein College of Medicine. Dr. Kane received his B.A. from Cornell University and his M.D. from the New York University School of Medicine. He currently directs the NIMH-funded Intervention Research Center for the Study of Schizophrenia at The Zucker Hillside Hospital. He has been a member of the Board of Scientific Counselors for NIMH, and he has served on the council of the American College of Neuropsychopharmacology. He has chaired the NIMH Psychopathology and Psychobiology Review Committee as well as the Psychopharmacologic Drugs Advisory Committee of the Food and Drug Administration.
Dr. Kane is a recipient of the Arthur P. Noyes Award in Schizophrenia, the NAPPH Presidential Award for Research, the American Psychiatric Association Foundations' Fund Prize for Research, the Kempf Fund Award for Research Development in Psychobiological Psychiatry, the Lieber Prize for Outstanding Research in Schizophrenia, the Heinz E. Lehmann Research Award from New York State, and the Dean Award from the American College of Psychiatrists."
~
Major NIMH Research Project to Test Approaches to Altering the Course of Schizophrenia:
From the NIMH news press release
"The National Institute of Mental Health (NIMH) is launching a large-scale research project to explore whether using early and aggressive treatment, individually targeted and integrating a variety of different therapeutic approaches, will reduce the symptoms and prevent the gradual deterioration of functioning that is characteristic of chronic schizophrenia.
The Recovery After an Initial Schizophrenia Episode (RAISE) project is being funded by NIMH with additional support from the American Recovery and Reinvestment Act (ARRA). RAISE is a model example of how money from the Recovery Act can accelerate science related to public health problems and potentially benefit those citizens most in need.
"This new initiative will help us determine whether intervention that is started early, incorporates diverse treatment and rehabilitation approaches, and is sustained over time, can make it possible for more people with schizophrenia to return successfully to work and school," said NIMH Director Thomas R. Insel, M.D. "Moreover, the interventions being tested will be designed from the outset to be readily adopted in real-world health care settings and quickly put into practice."
Despite the availability of moderately effective treatments, such as antipsychotic medications and various psychosocial interventions, people with schizophrenia often do not receive treatment until the disease is already well-established, with recurrent episodes of psychosis, resulting in costly multiple hospitalizations and disabilities that can last for decades. Periods of unemployment, homelessness, and incarceration are common, making schizophrenia a costly disease for individuals, their families, and the community at large.
~
Of course I have an opinion
PhRMA spends millions a day lobbying Congress, the doctor that heads this $40 million dollar study was/is on the FDA psychopharmacology committee that (for example)approved Seroquel for recommended use in children in the last FDA meeting, if you pay attention to anything I've written, pay attention to how the drug companies always have an investment in a positive outcome in these studies (meaning drugs will be promoted as a prevention action to "prevent" SZ and "maintain" SZ.
I'd like to see $40 million dollars fund a Soteria House, where clients can live drug-free, and longer lives, as the medications are factually known to shrink the brain, increase cancer risk and host deadly side effects. John Kane taught a class titled Benefits and Risks of Antipsychotic Medication, a Focus on Sedation, and sedation is a key word to use here.
Antipsychotics, in my opinion based on seeing them used on my daughter for a decade are nothing more than a chemical straight jacket, sedating, and dulling life for those who take them, especially Schizophrenics who take high doses for years. People who take the new-age depression drugs Abilify and Seroquel (those would be the same antipsychotics, just marketed to the consumer as antidepressants) should take heed, that they are taking drugs that reduce lifespan and carry risk more than one would want to ever imagine. Permanent movements, loss of memory, weight gain, heart failure and death just for starters.
The outcome of the NIMH study will be nothing more than a continuance of the medication based psychiatric paradigm we have in place now. Just watch.
Soteria House, a recovery model -wikipedia
"Soteria is a community service that provides a space for people experiencing mental distress or crisis. Based on a recovery model, common elements of the Soteria approach include primarily non-medical staffing; preserving resident's personal power, social networks, and communal responsibilities; finding meaning in the subjective experience of psychosis by "being with" clients; and no or minimal use of antipsychotic medication (with any medication taken from a position of choice and without coercion).[1] Soteria houses are often seen as gentler alternatives to a psychiatric hospital system perceived as authoritarian, hostile or violent and based on routine use of psychiatric (particularly antipsychotic) drugs. Soteria houses are sometimes used as "early intervention" or "crisis resolution" services."
Further reading: (links below are from Furious Seasons mental health news blog, by Philip Dawdy, including the study descriptions below)
Furious Seasons,"December 05, 2008,Lancet Editorial Slams Atypical Antipsychotic Safety, Efficacy As "Spurious"
The infamous PRIME study of Zyprexa used to allegedly prevent psychosis in kids.-Furious Seasons blog
A 2006 study showing that the use of atypicals in treating agitation in Alzheimer's was no more effective than placebo.
The 2006 CUTLASS study.
A 2007 subset of the CATIE study showing that atypicals only provided small cognition gains versus older drugs.
A 2007 study showing atypicals were not better than placebo in treating Alzheimer's.
A 2008 study showing that placebo outperformed atypicals in treating aggression in what were dubebd low IQ patients.
A 2008 study showing atypicals did not outperform older drugs in treating first episode psychosis.
A 2008 study showing that atypicals were detrimental to patients with dementia.
A 2008
study showing that atypicals were killing elderly patients at a shocking rate.A 2008 study showing that atypicals are very risky drugs for children versus older antipsychotics.
Posts
2 comments:
Medicines are for disease. The illness of schizophrenia or whatever mental illness is not lab test detectable. The term medicines for mental illness is a pure metaphor or colloquialism.
To apply a purely med-drug-chemical solution to mental illness, that is proven not be chemical, is insanity in itself.
Like breast cancer and AIDS research funding , someone should force the government to fund other methods of treatment (of M.I.) based on the science facts of "mental illness" and history. apa.org/monitor/feb00/schizophrenia.html
LINK
and more
Steve Coe 2002
To the Editor:
Courtenay Harding’s March 10 column, "Beautiful Minds Can Be Reclaimed," clearly articulates what many in the public mental health community know to be true. It’s now time for government funding systems to catch up with the most effective treatment models available (i.e., highly successful recovery-oriented models--like the ones Dr. Harding studied--that emphasize self-determination and peer support).
Unfortunately, the financial incentives built into current Medicaid regulations (which finances 95% of the public mental health system) favor models that reward providers for chalking up high numbers of face-to-face visits with clinic-based psychiatrists. We should instead be directing our public mental health dollars toward community-based models that help people with mental illness explore job opportunities, return to school, and build a social network outside of the mental health system; models which, as of now, receive only scant financial support compared to clinic-based, Medicaid-funded programs.
State and federal mental health officials need to overhaul antiquated Medicaid regulations as soon as possible so people with mental illness can finally end their "careers" as professional mental patients and begin lives as productive citizens in our community.
Sincerely,
Steve Coe
Executive Director Community Access, Inc. (Manhattan)
President-elect New York State Association for Community Living
Post a Comment